Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, July 3, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Amicus Therapeutics, Inc. (NASDAQ: FOLD), Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), Epizyme, Inc. (NASDAQ: EPZM) and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4395-100free.
Amicus Therapeutics, Inc. Analyst Notes
On June 30, 2014, Amicus Therapeutics, Inc. (Amicus) issued updates on its second Phase 3 study (Study 012) of migalastat monotherapy for Fabry patients with amenable mutations. According to the Company, the 18-month primary treatment period has completed with top-line data from Study 012 expected in Q3 2014. If successful, Study 012 will trigger the process for European regulatory approval of migalastat monotherapy. John F. Crowley, Chairman and CEO of Amicus commented, "We are very pleased to be advancing our Fabry monotherapy chaperone program into the final stages of drug development for Fabry patients with amenable mutations. Following on the heels of our recent positive results from our first Phase 3 registration Study 011, we are on track to report data in the third quarter of this year from Study 012, in which patients have volunteered to switch from ERT to our oral chaperone migalastat as their only therapy for Fabry disease." Crowley added, "We also plan to meet with the Food and Drug Administration in the fourth quarter of this year to discuss the data from both of our Phase 3 Fabry monotherapy studies, to determine the fastest U.S. registration pathway for migalastat." The full analyst notes on Amicus are available to download free of charge at:
Conatus Pharmaceuticals Inc. Analyst Notes
On June 30, 2014, Conatus Pharmaceuticals Inc.'s (Conatus) stock increased 8.71% to end the day at $9.11, compared to the previous day's closing price at $8.38. The Company's stock climbed 47.17% over the past one trading month, compared to the Nasdaq Composite which rose 3.90% during the same trading period. The full analyst notes on Conatus are available to download free of charge at:
Dicerna Pharmaceuticals, Inc. Analyst Notes
On June 30, 2014, Dicerna Pharmaceuticals, Inc. (Dicerna) announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1) - a rare inherited liver disorder that often results in progressive and severe kidney damage. The studies showed that DCR-PH1 provides long-term inhibition of HAO1, a gene implicated in the pathogenesis of PH1. In a genetically modified mouse model of PH1, researchers reported a 97% reduction of the HAO1 transcript in the liver following a single dose of DCR-PH1. "Physicians, patients and families managing PH1 currently have limited to no effective treatment for this severe and progressive disease," noted Craig B. Langman, M.D., Chair of the workshop and the Isaac A. Abt, M.D., Professor of Kidney Diseases, and Head, Kidney Diseases, at the Ann & Robert H. Lurie Children's Hospital of Chicago and the Feinberg School of Medicine of Northwestern University. "Based on these encouraging preclinical data, we look forward to beginning clinical trials to determine the potential role of DCR-PH1 in the treatment of PH1." The full analyst notes on Dicerna are available to download free of charge at:
Epizyme, Inc. Analyst Notes
On June 10, 2014, Epizyme, Inc. (Epizyme) announced the acceptance of its abstract EPZ-6438 for oral presentation at the American Society of Hematology (ASH) Meeting on Lymphoma Biology. The presentation will be held from August 10 to 13, 2014 in Colorado Springs, Colorado. The presentation will encompass findings characterizing the activity of EPZ-6438, a small molecule inhibitor of EZH2, in pre-clinical models of non-Hodgkin lymphoma (NHL), both as a single agent and in combination with NHL standards of care. It will also highlight the early clinical experience from an ongoing Phase 1 study of EPZ-6438 (E7438) in patients with advanced malignancies, including NHL. The full analyst notes on Epizyme are available to download free of charge at:
Array BioPharma, Inc. Analyst Notes
On June 30, 2014, Array Biopharma Inc.'s (Array) stock increased 7.29% to end the day at $4.56, compared to the previous day's closing price at $4.25. The Company's stock increased 8.57% over the past one trading month, compared to the Nasdaq Composite which rose 3.90% during the same trading period. The full analyst notes on Array are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.